Sotagliflozin to Protect Heart During Lymphoma Treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This study tests whether a heart-protective medication called sotagliflozin can prevent heart damage caused by strong chemotherapy drugs used to treat newly diagnosed lymphoma. You would take this medication during and after your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have newly diagnosed lymphoma (not been treated before)
- Your cancer treatment plan includes high-dose anthracycline chemotherapy (a strong type of chemo)
- You are in good enough health to tolerate treatment (ECOG score 0–3, meaning you can do most daily activities)
- You have never received anthracycline chemotherapy or other cancer treatments before
- Your heart pumps normally (ejection fraction ≥40%, meaning your heart is strong enough)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
This study tests if a drug can help suppress sugar uptake in the heart for clearer imaging. It may help researchers understand how to better see heart problems.
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Hear when a new Anthracycline-induced Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.